Research programme: diagnostic and therapeutic agents- Indi Molecular

Drug Profile

Research programme: diagnostic and therapeutic agents- Indi Molecular

Alternative Names: Akt PCC; Akt specific branched peptide triligand - Caltech/Integrated Diagnostics; Protein catalysed capture agents - Indi Molecular

Latest Information Update: 28 May 2015

Price : $50

At a glance

  • Originator California Institute of Technology/CalTech; Integrated Diagnostics
  • Class Diagnostic agents; Imaging agents; Peptides
  • Mechanism of Action Positron-emission tomography enhancers; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 May 2014 Indi Molecular and Sigma Aldrich enters into a co-development agreement to explore the use of protein catalysed capture agents to specifically interact with proteins
  • 26 Oct 2011 Integrated Diagnostics licenses click chemistry technology from the Scripps Research Institute
  • 26 Oct 2011 Integrated Diagnostics and California Institute of Technology enters into collaboration for development of synthetic diagnostic and therapeutic agents based on click chemistry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top